HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arizona Supplement Firm’s Problems Start With COVID-19 Claims, Reach SARMS, ED Drug

Executive Summary

CDER notes in update to COVID-19 enforcement and other actions that Umbrella Labs made unlawful claims to prevent and treat the virus. Announcement didn’t note those claims weren’t first among violations identified in a warning letter to the firm.

You may also be interested in...



California ‘SARMs’ Business Doesn’t Fool FDA Stating ‘Research Only’ On Supplement Labels

In addition to SARMs-containing supplements, agency officials found on Warrior Labz SARMs’ website products offered for sale containing drugs indicated for erectile dysfunction. Product labeling states, “By purchasing from Warrior Labz SARMS you agree that you are purchasing Research Chemicals.”

With Seizure in Florida, FDA Targets Kratom As Unsafe For Any Use

Kratom industry says complaint filed in Florida federal court shows FDA’s switching reasons to stop all sales of the ingredient in the US.

Schedule Kratom? Promoted By Former US FDA Commissioner, Opposed By Former Top HHS Official

Former commissioner Scott Gottlieb and former HHS health chief Brett Giroir make clear they haven’t changed their minds in Twitter posts following FDA kratom seizure announcement.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel